GRAIL

History

Year	Detail
2016	Grail company was founded and announced to focus on early cancer detection.
2017	The company received $ 1 billion in Series B funding after receiving $100 million in a Series A funding round.
2020	The company announces completion of series D funding of $390M. The funding provides resources to the company to develop and authorize blood-based cancer screening tests.
	The company partners with the UK's National Health Service to make available the Galleri, a multi-cancer early-detection blood test.
2021	Illumina acquired Grail in a $8 billion deal. Illumina holds the Grail as a separate company after its acquisition during the regulatory review by the European Commission's.
2022	The company partnered with AstraZeneca to develop companion diagnostic tests to enable the treatment of early-stage cancer.
2023	The company introduced a methylation-based solution to accelerate cancer research in the post-diagnosis setting.